Chonnam Med J.  2011 Aug;47(2):124-126. 10.4068/cmj.2011.47.2.124.

A Case of Stent Thrombosis Occurred at 5 Years after Sirolimus-Eluting Stent Implantation

• Kim SA
• Lim SY

• KMID: 2048797
• DOI: http://doi.org/10.4068/cmj.2011.47.2.124

Abstract

Drug-eluting stents (DES) have reduced the rate of repeated revascularization of target lesions. For this reason, DES are considered to be superior to bare-metal stents in reducing the restenosis rate. However, some problems have been reported after implantation of DES. One of them, stent thrombosis, has arisen as a fatal complication. Dual antiplatelet therapy is recommended for at least 12 months after implantation of DES to prevent stent thrombosis. Here, we report a case of very late stent thrombosis that occurred 1 week after discontinuation of clopidogrel at 5 years (1832 days) after implantation of a sirolimus-eluting stent.

Keyword

Drug-eluting stent; Thrombosis; Myocardial infarction

MeSH Terms

Drug-Eluting Stents
Myocardial Infarction
Stents
Thrombosis
Ticlopidine
Ticlopidine

Figure

• 

  FIG. 1 (A) Emergent coronary angiogram revealed a thrombotic total occlusion at the proximal right coronary artery. (B) The occluded right coronary artery was revascularized successfully by balloon angioplasty with a 3.0×20 mm balloon.

Reference

1. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002. 346:1773–1780.

2. Sibbing D, Laugwitz KL, Bott-Flügel L, Pache J. Very late stent thrombosis 42 months after implantation of sirolimus-eluting stent and discontinuation of antiplatelet therapy. Case Report Med. 2009. 2009:713292.

3. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006. 48:193–202.

4. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation. 2004. 109:701–705.

5. Rossini R, Capodanno D, Lettieri C, Musumeci G, Nijaradze T, Romano M, et al. Prevalence, predictors, and long-term prognosis of premature discontinuation of oral antiplatelet therapy after drug eluting stent implantation. Am J Cardiol. 2011. 107:186–194.

6. Stone GW, Aronow HD. Long-term care after percutaneous coronary intervention: focus on the role of antiplatelet therapy. Mayo Clin Proc. 2006. 81:641–652.

7. Vink MA, Dirksen MT, Suttorp MJ, Tijssen JG, van Etten J, Patterson MS, et al. 5-year follow-up after primary percutaneous coronary intervention with a paclitaxel-eluting stent versus a bare-metal stent in acute ST-segment elevation myocardial infarction: a follow-up study of the PASSION (Paclitaxel-Eluting Versus Conventional Stent in Myocardial Infarction with ST-Segment Elevation) trial. JACC Cardiovasc Interv. 2011. 4:24–29.

8. Park DW, Yun SC, Lee SW, Kim YH, Lee CW, Hong MK, et al. Stent thrombosis, clinical events, and influence of prolonged clopidogrel use after placement of drug-eluting stent data from an observational cohort study of drug-eluting versus bare-metal stents. JACC Cardiovasc Interv. 2008. 1:494–503.

9. Tanzilli G, Greco C, Pelliccia F, Pasceri V, Barillà F, Paravati V, et al. Effectiveness of two-year clopidogrel + aspirin in abolishing the risk of very late thrombosis after drug-eluting stent implantation (from the TYCOON [two-year ClOpidOgrel need] study). Am J Cardiol. 2009. 104:1357–1361.

10. Chen KY, Rha SW, Li YJ, Poddar KL, Jin Z, Minami Y, et al. Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation. 2009. 119:3207–3214.

11. Suh JW, Lee SP, Park KW, Lee HY, Kang HJ, Koo BK, et al. Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial. J Am Coll Cardiol. 2011. 57:280–289.